ADIL

Business Context and Reporting Period

Company: ADIAL PHARMACEUTICALS, INC. (ADIL)
Filing Type: Form 10-Q
Period: Quarter ended September 30, 2024
Business Overview: Adial is a clinical-stage biopharmaceutical company focused on developing therapeutics for addiction and related disorders. Its lead candidate, AD04 (ondansetron), is being developed for Alcohol Use Disorder (AUD). The company sold its Purnovate subsidiary assets in 2023, which are now classified as discontinued operations.

Key Financial Metrics

Debt and Liquidity: The company has no long-term debt. Total current liabilities as of September 30, 2024, were $829,046. The company holds $5.2 million in cash, with approximately $4.5 million in non-FDIC insured accounts.

Material Changes vs. Prior Period

• Net Loss Increase: The YTD 2024 net loss of $11.1 million represents a significant increase compared to the $3.2 million loss in YTD 2023. This is primarily driven by a one-time non-cash inducement expense of $4.46 million related to warrant exercises and a $443,000 loss from an equity method investment in Adovate.
• R&D Expenses: Research and development expenses increased by approximately $1.5 million YTD 2024 compared to the prior year, driven by Phase 1b clinical trial costs and chemistry, manufacturing, and controls (CMC) expenses.
• Financing Activity: The company raised approximately $7.8 million in net cash from financing activities YTD 2024, compared to $0.75 million in the prior year. This was achieved through an At-the-Market (ATM) offering ($4.0 million net) and warrant exercises ($3.8 million net).
• Discontinued Operations: Unlike the prior year, which included a $1.9 million gain from the sale of Purnovate assets, there were no discontinued operations in the current period.

Guidance, Outlook, and Risks

Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. Current cash reserves are not sufficient to fund operations for the next twelve months. Without additional financing, the company may need to delay or scale back R&D programs.

Outlook:

• Development Plans: The company plans to initiate a Phase III study for AD04 in the second half of 2025. Implementing accelerated development plans would exhaust current cash by Q2 2025.
• Capital Needs: The company estimates it will require between $13 million and $16 million over the next 12 months to fund development and operations, with $9-12 million contingent on accelerated plans.
• Regulatory: The FDA has indicated acceptance of heavy-drinking-day endpoints for AUD approval. The company is focused on completing clinical development for specific genetic subgroups.

Risks and Contingencies:

• Internal Controls: The company identified material weaknesses in internal controls over financial reporting, including lack of formal risk assessment, insufficient segregation of duties, and inadequate documentation.
• Liquidity Risk: Failure to raise additional capital on acceptable terms could force the company to cease operations.
• Related Party Transactions: Significant transactions exist with Adovate (equity method investment) and the University of Virginia Patent Foundation (licensing).

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $5.2 million cash balance against the projected $13-16 million funding requirement for the next 12 months.
• Warrant Inducement Expense: Confirm the accounting treatment and impact of the $4.46 million non-cash inducement expense on the net loss.
• Internal Control Remediation: Review the progress of the remediation plan for material weaknesses in internal controls over financial reporting.
• ATM Agreement Status: Monitor the remaining capacity and utilization of the At-the-Market offering agreement with H.C. Wainwright & Co.
• Equity Method Investment: Assess the financial health of Adovate, LLC, in which Adial holds an 11.61% stake, as losses here directly impact Adial's bottom line.